Jefferies Financial Group upgraded shares of Idorsia (OTCMKTS:IDRSF) from a hold rating to a buy rating in a research note released on Thursday, The Fly reports.
IDRSF has been the topic of several other reports. Barclays restated an overweight rating on shares of Idorsia in a research report on Monday, July 19th. Credit Suisse Group restated an outperform rating on shares of Idorsia in a research report on Tuesday, July 6th. Finally, JPMorgan Chase & Co. restated a neutral rating on shares of Idorsia in a research report on Wednesday, July 28th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of Buy.
Shares of IDRSF opened at $24.66 on Thursday. The firm’s 50-day moving average is $25.07 and its two-hundred day moving average is $26.50. Idorsia has a twelve month low of $22.68 and a twelve month high of $33.25.
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The firm targets patients who are suffering with Fabry disease, insomnia, Cerebral vasospasm associated with aSAH and systemic lupus erythematosus.
Read More: Commodities
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.